Artificial thymic organoids (ATOs) allow the selective differentiation of chimeric antigen receptor (CAR)-transduced human iPSCs into CAR-T cells. In this issue of Cell Stem Cell, Wang et al. now use ATOs to produce human CD19⁺ CAR-T cells that mimic conventional CAR-T cells and effectively control the progression of human CD19⁺ leukemia in an animal model.

中文翻译：

---

成功的类器官介导生成 iPSC 衍生的 CAR-T 细胞

人工胸腺类器官 (ATO) 允许将嵌合抗原受体 (CAR) 转导的人类 iPSC 选择性分化为 CAR-T 细胞。在本期Cell Stem Cell中，Wang 等人。现在使用 ATO 生产人类 CD19 ⁺ CAR-T 细胞，模拟常规 CAR-T 细胞，并在动物模型中有效控制人类 CD19 ^{+白血病的进展。}